Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

L. R. Martins; P. Lúcio; A. Melão; I. Antunes; B. A. Cardoso; R. Stansfield; M. T.S. Bertilaccio; P. Ghia; D. Drygin; M. G. Silva; J. T. Barata

doi:10.1038/leu.2013.232

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

L. R. Martins, P. Lúcio, A. Melão, I. Antunes, B. A. Cardoso, R. Stansfield, M. T.S. Bertilaccio, P. Ghia, D. Drygin, M. G. Silva, J. T. Barata

Research output: Contribution to journal › Letter › peer-review

63 Citations (Scopus)

Original language	English
Pages (from-to)	179-182
Number of pages	4
Journal	Leukemia
Volume	28
Issue number	1
DOIs	https://doi.org/10.1038/leu.2013.232
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2013.232

Cite this

@article{20eb289bc2274a24ad31f8260cb5b944,

title = "Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia",

author = "Martins, {L. R.} and P. L{\'u}cio and A. Mel{\~a}o and I. Antunes and Cardoso, {B. A.} and R. Stansfield and Bertilaccio, {M. T.S.} and P. Ghia and D. Drygin and Silva, {M. G.} and Barata, {J. T.}",

note = "Funding Information: We are grateful to all the patients who contributed to this study. We thank Dr Riccardo Dalla-Favera for providing the MO1043 cell line and Dr John Byrd for providing the WaC3CD5 cell line. We also thank the Helena Ala{\`i}z (cytogenetics section of the Hemato-oncology lab at Instituto Portugu{\^e}s de Oncologia). This work was mainly supported by the grant PIC/IC/83193/2007 from Fundac¸{\~a}o para a Ci{\^e}ncia e a Tecnologia; and also by Associazione Italiana per la Ricerca sul Cancro AIRC (Investigator Grant and Special Program Molecular Clinical Oncology – 5 per mille #9965), Ricerca Finalizzata 2010 – Ministero della Salute, Roma. LRM received an FCT-SFRH PhD fellowship.",

year = "2014",

doi = "10.1038/leu.2013.232",

language = "English",

volume = "28",

pages = "179--182",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

AU - Martins, L. R.

AU - Lúcio, P.

AU - Melão, A.

AU - Antunes, I.

AU - Cardoso, B. A.

AU - Stansfield, R.

AU - Bertilaccio, M. T.S.

AU - Ghia, P.

AU - Drygin, D.

AU - Silva, M. G.

AU - Barata, J. T.

N1 - Funding Information: We are grateful to all the patients who contributed to this study. We thank Dr Riccardo Dalla-Favera for providing the MO1043 cell line and Dr John Byrd for providing the WaC3CD5 cell line. We also thank the Helena Alaìz (cytogenetics section of the Hemato-oncology lab at Instituto Português de Oncologia). This work was mainly supported by the grant PIC/IC/83193/2007 from Fundac¸ão para a Ciência e a Tecnologia; and also by Associazione Italiana per la Ricerca sul Cancro AIRC (Investigator Grant and Special Program Molecular Clinical Oncology – 5 per mille #9965), Ricerca Finalizzata 2010 – Ministero della Salute, Roma. LRM received an FCT-SFRH PhD fellowship.

PY - 2014

Y1 - 2014

UR - http://www.scopus.com/inward/record.url?scp=84891855786&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.232

DO - 10.1038/leu.2013.232

M3 - Letter

C2 - 23925046

AN - SCOPUS:84891855786

VL - 28

SP - 179

EP - 182

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

UN SDGs

Access to Document

Other files and links

Cite this